In order to overcome the side effects associated with the invasive subcutaneous injection of biological macromolecular drugs, Fukuta et al. investigated the IP-mediated delivery of an antibody and the TNF-α drug etanercept (recombinant human TNF-α receptor: Fc fusion protein) into the skin, and evaluated their therapeutic efficiency against imiquimod (IMQ)-induced psoriasis [48]. Here, TNF is linked to psoriasis.